Related Experiment Videos
[Clinical studies with antimicrobic agent "Dolcol" for chronic prostatitis].
Hinyokika Kiyo. Acta Urologica Japonica
|September 1, 1985
Summary
Pipemidic acid (PPA) effectively treated chronic prostatitis in 83.3% of patients. This study suggests PPA is a safe and beneficial option for managing this common male infection.
Area of Science:
- Urology
- Infectious Diseases
- Pharmacology
Context:
- Chronic prostatitis is a prevalent condition affecting middle-aged men.
- Accurate diagnosis relies on microscopic examination of prostatic secretions and urine post-massage.
- This study investigated a specific treatment regimen for chronic prostatitis.
Purpose:
- To evaluate the efficacy and safety of Pipemidic acid (PPA) in treating chronic prostatitis.
- To assess treatment outcomes based on subjective symptoms and objective clinical findings.
Summary:
- Twenty-four male outpatients diagnosed with chronic prostatitis were treated with Pipemidic acid (PPA).
- Patients received 2 tablets of PPA three times daily for 7-30 days.
- An overall effective rate of 83.3% was observed, with no reported side effects.
Impact:
- Pipemidic acid (PPA) demonstrates significant therapeutic potential for chronic prostatitis.
- The findings support PPA as a viable treatment option, contributing to improved patient outcomes.
- This research provides evidence for the effectiveness of PPA in managing a common urological infection.